Please check your internet connection and try again.
# IV Hydrocortisone for Acute Asthma
## Overview
Intravenous hydrocortisone is a corticosteroid used as an adjunct therapy in managing acute asthma exacerbations, particularly in patients who do not respond adequately to inhaled bronchodilators or who have severe symptoms. It works by reducing airway inflammation.
## Primary Indications
Adjunctive treatment of moderate to severe acute asthma exacerbations in patients not responding adequately to initial bronchodilator therapy.
## Adult Dosing
* **Initial Dose:** 100 mg IV every 6 to 12 hours.
* **Continuous Infusion:** Some protocols may use a continuous infusion of 200 mg over 24 hours.
* **Duration:** Typically continued until the patient can tolerate oral corticosteroids and is improving, usually within 24-48 hours.
Dosing may vary based on institutional protocols and severity of exacerbation.
## Pediatric Dosing
* **Age 1 month to 12 years:** 2 mg/kg/dose IV every 6 hours. Maximum single dose: 80 mg.
* **Age 12 years and older:** Same as adult dosing (100 mg IV every 6 to 12 hours).
Dosing should be guided by institutional protocols and clinical response.
## Dose Adjustments
No specific dose adjustments are routinely recommended for hepatic or renal impairment, but prolonged use and associated adverse effects should be considered.
## Contraindications
* Known hypersensitivity to hydrocortisone or other corticosteroids.
* Systemic fungal infections.
* Caution in patients with active infections (viral, bacterial, parasitic).
## Adverse Effects
Common adverse effects with short-term IV use include hyperglycemia, electrolyte imbalances (hypokalemia), insomnia, mood changes, and increased susceptibility to infection. Long-term or high-dose use can lead to more significant effects like Cushingoid features, osteoporosis, adrenal suppression, and growth suppression in children.
## Key Drug Interactions
* **Potassium-depleting agents (e.g., loop diuretics):** Increased risk of hypokalemia.
* **Antidiabetic agents:** May decrease their effectiveness, requiring dose adjustments.
* **CYP3A4 inhibitors (e.g., ketoconazole, ritonavir):** May increase hydrocortisone levels.
* **CYP3A4 inducers (e.g., rifampin, phenytoin):** May decrease hydrocortisone levels.
## Monitoring
* Blood glucose levels, especially in diabetic patients or those with risk factors.
* Electrolytes (potassium).
* Clinical signs of asthma improvement (respiratory rate, wheezing, oxygen saturation).
* Signs of infection.
* For prolonged use: bone density, growth in children, HPA axis suppression.
## Clinical Pearls
* IV hydrocortisone provides a slower onset of action compared to inhaled bronchodilators and should not delay initial appropriate treatment with short-acting beta-agonists and ipratropium.
* It is most beneficial when given early in the exacerbation.
* Transition to oral corticosteroids as soon as clinically appropriate.
* Ensure adequate gastrointestinal absorption before transitioning to oral therapy.
***
*This information is intended for healthcare professionals. Always verify current prescribing information and consult relevant guidelines or drug compendia before making clinical decisions.*
